Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

The combination of targeted therapy with BRAF and MEK inhibitors has become the standard of care in patients with BRAF(V600E) mutant melanoma, but responses are not durable. In addition, the impressive clinical benefits with anti-PD-1 and anti-PD-L1 antibodies (Ab) in patients with heavily pretreate...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncoimmunology
Prif Awduron: Homet Moreno, Blanca, Mok, Stephen, Comin-Anduix, Begonya, Hu-Lieskovan, Siwen, Ribas, Antoni
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Taylor & Francis 2015
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006894/
https://ncbi.nlm.nih.gov/pubmed/27622011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1052212
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg